Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.75 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
| ▸ | CTSK | P43235 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111236 | 1.00 | ACE (0.76) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL111235 | 1.00 | ACE (0.76) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL28419447 | 0.98 | ACE (0.74) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL28419446 | 0.98 | ACE (0.74) | ACEPTPN1CA2CA1GPR132 | |
| Hydrochloric Acid SCHEMBL10622640 | 0.98 | ACE (0.74) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL4357736 | 0.94 | ACE (0.68) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL4356229 | 0.94 | ACE (0.68) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL6857183 | 0.92 | PTPN1 (0.69) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL10033681 | 0.92 | PTPN1 (0.69) | ACEPTPN1CA2CA1GPR132 | |
| SCHEMBL2632872 | 0.92 | PTPN1 (0.74) | ACEPTPN1CA2CA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912762-B | Water-soluble near-infrared two-region macromolecular fluorescent probe and preparation method and application thereof | 复旦大学 | 2023-02-10 | — | — | CN | claimed |
| CN-115433218-A | Amphiphilic BODIPY compound NBDP modified by multi-site hexaethylene glycol and preparation method and application thereof | 杭州师范大学 | 2022-12-06 | — | — | CN | claimed |
| CN-112929879-B | NBDP clustering-based wireless sensor network malicious node detection method | 电子科技大学 | 2022-05-03 | — | — | CN | claimed |
| CN-121397616-B | Emergency equipment communication test method, device, equipment, medium and product | 广州海格通信集团股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| CN-121471282-A | Dimer type Aza-BODIPY base molecule and preparation method and application thereof | 南京工业大学 | 2026-02-06 | — | — | CN | disclosed |
| CN-121248642-A | Tumor blood vessel blocking type photodiagnosis and treatment molecule and preparation method and application thereof | 南京工业大学 | 2026-01-02 | — | — | CN | disclosed |
| US-20260000710-A1 | Novel Treatments for Cardiovascular Related Disease | LA JOLLA INST FOR IMMUNOLOGY (US) | 2026-01-01 | — | — | US | disclosed |
| CN-119583285-A | OFDM signal receiving and processing system and method suitable for NAVDAT system | 重庆邮电大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118725169-A | Water-soluble near-infrared two-region chemiluminescent macromolecular fluorescent probe and preparation method and application thereof | 安徽师范大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-115334098-B | Enterprise digital system based on industrial PaaS technology | 中海油田服务股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-0174358-A1 | NOVEL DIASTEREOMER SALTS OF PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF AND PROCESS FOR THE SEPARATION OF OPTICALLY ACTIVE PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF | ALKALOIDA VEGYéSZETI GYáR (HU) | 1986-03-19 | — | — | EP | disclosed |
| WO-1985003932-A1 | NOVEL DIASTEREOMER SALTS OF PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF AND PROCESS FOR THE SEPARATION OF OPTICALLY ACTIVE PHENYLALANINE AND N-ACYL DERIVATIVES THEREOF | ALKALOIDA VEGYÉSZETI GYÁR (HU) | 1985-09-12 | — | — | WO | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0031877-B1 | OPTICALLY ACTIVE 1,2-BIS-(DIPHENYLPHOSPHINO)-COMPOUNDS, METAL COMPLEXES CONTAINING THEM AS CHIRAL LIGANDS AND THEIR USE | Degussa Aktiengesellschaft (DE) | 1983-02-02 | — | — | EP | disclosed |
| EP-0023730-B1 | CYCLOHEXYLCYCLOHEXANOATES, PROCESS FOR THEIR PREPARATION AND LIQUID-CRYSTAL MIXTURE CONTAINING THEM | MERCK PATENT GmbH (DE) | 1982-11-03 | — | — | EP | disclosed |
| US-4356324-A | CHIRAL LIGANDS FOR RHODIUM HYDROGENATION CATALYSTS | DEGUSSA AKTIENGESELLSCHAFT, A GERMAN CORP. (DE) | 1982-10-26 | — | — | US | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0031877-A1 | Optically active 1,2-Bis-(diphenylphosphino)-compounds, metal complexes containing them as chiral ligands and their use | Degussa Aktiengesellschaft (DE) | 1981-07-15 | — | — | EP | disclosed |
| EP-0023730-A1 | Cyclohexylcyclohexanoates, process for their preparation and liquid-crystal mixture containing them | MERCK PATENT GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000710-A1 | Novel Treatments for Cardiovascular Related Disease | HLA-DRB1, APOL1, MICA | ACE 1478/4885PTPN1 1519/4885CA2 4587/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | ACE 3749/4885PTPN1 118/4885CA2 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.